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Abstract
Despite the technological advancement in the biomedical science, cancer remains a life-threatening disease. In this
study, we designed an anticancer nanodelivery system using graphene oxide (GO) as nanocarrier for an active
anticancer agent gallic acid (GA). The successful formation nanocomposite (GOGA) was characterized using XRD,
FTIR, HRTEM, Raman, and UV/Vis spectroscopy. The release study shows that the release of GA from the designed
anticancer nanocomposite (GOGA) occurs in a sustained manner in phosphate-buffered saline (PBS) solution at pH
7.4. In in vitro biological studies, normal fibroblast (3T3) and liver cancer cells (HepG2) were treated with different
concentrations of GO, GOGA, and GA for 72 h. The GOGA nanocomposite showed the inhibitory effect to cancer
cell growth without affecting normal cell growth. The results of this research are highly encouraging to go further
for in vivo studies.
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Background
Despite concerted research effort to fight various diseases
to improve human health, cancer still remains as one of
the biggest challenges for human beings [1, 2]. Two major
methods can be used to overcome this problem. The first
is to develop and synthesize new anticancer drugs. And
the second is to develop new and effective delivery sys-
tems with the ability to improve the therapeutic profile
and efficacy of existing therapeutic agents [3, 4]. There-
fore, various nanocarrier-based therapeutic and diagnostic
agents such as liposome, carbon nanotubes, polymeric
nanoparticles, and dendrimers have been extensively stud-
ied to prolong the half-life of drug systemic circulation
and lower frequency of administration to minimize
systemic side effects of drugs. Drugs can be loaded or
attached via different mechanisms, such as embedding,
physical absorption, and hydrogen-bonding interactions
[5] resulting in the sustained release of drugs over longer
periods of time [2, 6, 7].
Recently, graphene and its chemically oxidized deriva-
tive, graphene oxide (GO) (a 2D hydrophilic carbon
material) [8–11], have been investigated for targeted
drug delivery for cancer therapy [12–19], biosensing,
and cancer photothermal therapy, as they have a propor-
tionally large surface area than many other materials,
ample functional groups on the surface, good photother-
mal properties, and/or low cytotoxicity [20, 21]. The
amphiphilic and planar structure of GO enable it to in-
corporate hydrophilic and/or hydrophobic biomolecules
which gives the opportunity to prevent its instability in a
medium [15, 18, 22]. In addition, the large surface area
and oxygen-containing functional groups of GO such as
phenol hydroxyl, epoxy, and carboxylic groups make it
ideal for providing high drug loading efficiency, good
dispersion, and easily functionalization [2, 23].
Gallic acid (GA), a polyhydroxylphenolic compound,
which has a wide range of biological applications such as
antiviral, antibacterial, antimelanogenic, antimutagenic,
anti-inflammatory, and anticancer activity, in a range of
cells is distributed in a variety of fruits, plants, and foods
[24–29]. In this study, we have selected GA as a model
drug to be loaded onto the as-prepared GO nanocarrier
to form a new nanocomposite (GOGA) for active drug
delivery and specific cell targeting system in normal
fibroblasts (3T3) and in liver cancer cells, HepG2. The
results from the X-ray diffraction (XRD), Fourier
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transform infrared (FTIR), Raman spectroscopy, TGA/
DTG, anticancer evaluation, and cytotoxicity as well as
release property of GA from GOGA nanocomposite into
aqueous media will be also discussed.
Methods
Materials
Graphite flakes with 100 meshes (Sigma), potassium per-
manganate (99 %), sulphuric acid (95–97 %), hydrochloric
acid (37 %), diethyl ether, ortho-phosphoric acid (85 %)
and hydrogen peroxide (35 %) by Riendemann chmidt,
gallic acid (97 % purity) (Sigma-Aldrich), and ethyl alcohol
(99.7 % v/v) (Hayman) were used in this work. All the
aqueous solutions were prepared using deionized water
(18.2 M Ω cm−1).
Characterization
The synthesized products were characterized by powder
X-ray diffraction (XRD-6000 diffractometer, Shimadzu,
Tokyo, Japan), with CuKα radiation (λ = 1.5406 Å) at
40 kV and 30 mA. FTIR (Thermo Nicolet model Nicolet
6700) was performed using the KBr disc method. Raman
spectra were collected using a UHTS 300 Raman spec-
trometer (WITec, Germany) with an excitation wave-
length at 532 nm. The structures of the GO nanocarrier
and GOGA nanocomposite were observed on a high-
resolution transmission electron microscope (HRTEM),
Tecnai G2 (FEI, USA). The samples were prepared by
placing a drop of a sonicated dispersion on a carbon grid
and dried at 37 °C for 24 h. The controlled release proper-
ties and the loading capacity were studied using a Lambda
35 spectrophotometer (PerkinElmer, Boston, MA).
Preparation of GO Nanocarrier and GOGA Nanocomposite
Graphene oxide was synthesized from graphite (Gr) by
the improved Hummers method [30]. A 9:1 mixture of
concentrated H2SO4/H3PO4 (360:40 mL) was added to a
mixture of graphite flakes (3.0 g, 1 wt equiv) and
KMnO4 (18.0 g, 6 wt equiv). The reaction was then
heated to 50 °C and stirred for 12 h. The reaction was
cooled to room temperature and poured onto ice
(400 mL) with 30 % H2O2 (3 mL). The obtained suspen-
sion was centrifuged at 4000 rpm for 5 min and then
washed with 200 mL of deionized water (DIW), 200 mL
of HCl (37 %), and then with 200 mL of ethanol, re-
spectively. The obtained product was coagulated with
200 mL of diethyl ether and then filtered by Omnipore™
membrane with a 0.2-μm pore size. The obtained GO
on the filter was dried in an oven at 40 °C [30]. A 1 %
of pure drug (GA) was dissolved in DIW and 0.1 g of
GO was added and the pH fixed at 4.71. The mixture
was stirred for 16 h and then washed with DIW to re-
move unreacted drug. The GOGA nanocomposite was
collected via filtration and dried in an oven at 40 °C.
In Vitro Cytotoxicity Experiment
The normal mouse fibroblast cell lines 3T3 and human
hepatocellular liver carcinoma cell lines HepG2 were ob-
tained from American Type Culture Collection (ATCC,
VA, USA), and these cells were cultured in DMEM and
RPMI medium (Nacalai, Japan) supplemented with 10 %
(v/v) fetal bovine serum (FBS) and 1 % antibiotic solu-
tion, respectively. To determine the cell viability, healthy
viable cells were seeded to cell culture plates (1 × 104)
once reach the 80 % of confluency in a cell culture flask
and seeded cells were allowed to adhere overnight earlier
to the nanocompound treatment with different doses
(0.781–50 μg/mL). The cells without any treatment were
served as a negative control, and another set of cells
were treated with vehicle control (0.1 % dimethyl sulfox-
ide (DMSO)). Treated cells were incubated for 72 h;
after the incubation period, cell counting reagent (CCK-
8 solution; Dojindo Lab, Japan) was then added to each
cell culture well and placed in an incubator for 3 h at
37 °C in a humidified atmosphere with 5 % CO2. After
the incubation period with cell counting reagent, the 96-
well cell culture plates were measured at 450 nm by a
microplate reader (BioTek Instruments Inc., VT, USA).
The cell viability percentage was determined according
to the kit protocol, and cell viability percentage was plot-
ted on a graph.
Drug-Release Procedure
To study the controlled-release characteristics of GA
loaded on GOGA nanocomposite, a pH 7.4 solution was
used, which has a similar pH of blood. Various studies
show that different anions such as HPO4
−2 and H2PO4
−
have an affect on the rate of drug release [31–33]. The
release rate of GA from GOGA nanocomposite was car-
ried out by adding 14 mg of GOGA nanocomposite into
10 mL of phosphate-buffered solution (pH = 7.4) and used
after 10 days. The accumulated release amount of GA
from GOGA nanocomposite was measured at λmax =
264 nm at room temperature.
Results and Discussion
X-ray Diffraction
Figure 1 depicts XRD patterns of pristine graphite (Gr),
GO nanocarrier, and GOGA nanocomposite. The diffrac-
tion pattern of pure Gr (Fig. 1(a)) shows a very intense,
sharp peak at 2θ = 26.27°, attributed to the diffraction of
the (002) graphite plane composed of highly organized
layers with an interlayer spacing of 0.34 nm [34, 35]. After
oxidative exfoliation of Gr, the characteristic peak of Gr
was no longer visible and a new strong sharp peak at 2θ =
10.15° was observed which is attributed to the diffraction
of the (001) for GO (Fig. 1(b)). An increase in the inter-
layer distance of GO (0.87 nm) might be due to the exfoli-
ation of Gr layers and the formation of oxygen-containing
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functional groups such as hydroxyl, epoxy, and carboxyl
[36], as well as the intercalated water molecules on the
surface of GO interlayer’s [37, 38]. The inset shows the
XRD patterns of pure GA with several intense and sharp
crystalline peaks at 2θ values of 16.22°, 25.36°, and 27.64°,
corresponding to the characteristic of an organic molecule
with crystalline property [39]. In contrast, GOGA nano-
composite (Fig. 1(c)) shows amorphous characteristic, lack-
ing of crystalline peaks in contrast to the XRD patterns of
pure drug, GA. Since the characteristic peaks of GA were
not observed in the XRD patterns of GOGA nanocompos-
ite, it proved that the loading of the drug to the GO carrier
has taken place. The successful formation of GOGA nano-
composite was further confirmed by other complimentary
techniques such as FTIR, Raman, and UV-visible spectros-
copy, which will be discussed in other sections. Moreover,
the result shows that there are no big difference between
the diffractograms of GO and GOGA nanocomposite, con-
firming that the loading procedure did not affect the phase
change in the resulting GO nanocarrier.
Infrared Spectroscopy
Figure 2 shows the FTIR spectra of pure Gr, GO, and
GOGA nanocomposite. Pure Gr spectrum (Fig. 2(a))
shows a broad peak at 3449 cm−1 attributed to the exist-
ence of moisture in the pristine Gr [34]. The peak at
1635 cm−1 is assigned to stretching vibrations of C=C
bonds. Figure 2(b) shows an intense broad peak for GO
nanocarrier at 3422 cm−1 due to the stretching –OH
band. The existence of –OH groups in GO can be
bonded to the various sites of the carbon skeleton,
resulting in the broadening of the peak [40]. The peak at
1730 cm−1 is attributed to the stretching vibration of C=O
bonds presence in carboxylic acid and carbonyl groups.
The low intensity C=C bonds at 1627 cm−1 corresponding
to remaining sp2 character of graphite [41]. In addition,
the peaks in the region of 1362 to 1049 cm−1 might be
due to the COC/COH bonds [40]. Figure 2(c) indicates
the characteristic bands of pure GA at 3286 cm−1 (acidic
O–H stretching), 1712 cm−1 (presence of phenol group),
1617 cm−1 (C=C stretching vibration of aromatic ring),
1247 cm−1 (presence of carboxylic groups), 1026 cm−1
a
b
c
Fig. 1 XRD patterns of Gr (a), GO nanocarrier (b), and GOGA
nanocomposite (c). The inset shows the XRD patterns of pure GA
a
b
c
d
Fig. 2 Fourier transform infrared spectra for a Gr, b GO, c GA, and d
GOGA nanocomposite
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(C–O stretching of carboxylic group), and 731 cm−1 (δCC
benzene ring vibrations) [42, 43].
The peak observed in Fig. 2(d) for GOGA nanocom-
posite at around 3446 cm−1 can be assigned to the O–H
functional groups from carboxyl or phenols. After load-
ing of the drug, GA into GO nanocarrier with the char-
acteristic bands of 1730 and 1628 cm−1 with lower
intensity still remained. The infrared spectrum of GOGA
nanocomposite (Fig. 2(d)) shows the characteristic peaks
of both GO nanocarrier and GA which suggest the
successful formation of the nanocomposite.
Raman Spectroscopy
Raman spectroscopy was used to analyze the disorder
and defects in crystal structure of graphite and its de-
rivative (GO). In order to obtain disorder, the intensity
ratio between the disorder-induced D band and the G
band (ID/IG) can be measured. Previous works proved
that the ID/IG ratio strongly depends on the amount of
disorder in the graphitic material [44]. The Raman
spectrum of Gr, GO, and GOGA nanocomposite is
shown in Fig. 3. It is clear that significant structural
changes took place during the chemical transformation
from Gr to GO (Fig. 3(a, b)). Usually, all sp2 carbon
forms have the G band, which appears from the first-
order Raman scattering [45–47]. The G band is observed
at 1579, 1601, and 1599 cm−1, while the D band is dis-
tinguished at 1352, 1355, and 1353 cm−1 for Gr, GO,
and GOGA nanocomposite, respectively. The D band
corresponded to the presence of disorder in the sp2
carbon network, and broadening of D bands in GO can
be due to a decrease of the sp2 domain size, caused by
the creation of defects, vacancies, and distortions during
oxidation [48]. The 2D band (G′ band) appears at 2706,
2902, and 2933 cm−1 in Raman spectrum corresponding
to the second-order dispersive Raman mode for the Gr,
GO, and GOGA nanocomposite, respectively [46, 49].
Raman spectra of GO and GOGA nanocomposite
(Fig. 3(b, c)) show no significant shift in the D band and
G band. The increase of ID/IG of the GO nanocarrier
(0.96) when compared to the Gr (0.84) confirms that
grafting of oxygen-containing functional groups to the
graphitic planes has taken place [48].
Morphology Study Using HRTEM
High-resolution electron microscopy (HRTEM) was
used to further elucidate the morphology and disper-
sion of the compounds. Figure 4 shows the HRTEM
images of the GO nanocarrier and GOGA nanocom-
posite. It was revealed that the large sheets in GO
(Fig. 4a, b,) tend to agglomerate to each other, form-
ing a multilayered agglomerate. These sheets resemble
a wavy silk veil, transparent, and entangled with one
another [40]. The HRTEM images of GOGA nano-
composite (Fig. 4c, d) show GO forms similar to ag-
glomerate multilayer sheets, with the drug loaded into
the surface of GO nanocarrier.
Loading and Release Behavior of GA
The release profiles of GA from a physical mixture of
(GO-GA) and the GA from GOGA nanocomposite
into phosphate-buffered solution at pH 7.4 (blood
pH) are shown in Fig. 5. The fast release of GA from
the physical mixture was completed within 7 min at
pH 7.4 (Fig. 5a). This is due to the low electrostatic
attraction between the GA anions and GO nanocar-
rier. Figure 5b shows that the cumulative release rate
of GA into buffered solution at pH 7.4 is significantly
slower and sustained which is presumably due to the
anion-exchange process taking place between the GA
anions and the anions in the buffered solutions [50].
In addition, the initial burst release [51] observed in
the first 1 h (59 %) can be due to the surface charac-
teristics of GO material, the drug interactions, or/and
morphology and porous structure of the material [51].
The maximum percentage release of GA from the
GOGA nanocomposite reached 81 % in about
7200 min (or 5 days) at pH 7.4. From the calibration
curve equation and using the ultraviolet instrument,
a
b
c
Fig. 3 Raman spectra of Gr (a), GO (b), and GOGA
nanocomposite (c)
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12 % GA loaded to the GO nanocarrier can be
obtained. As such, the percentage of GA released
from GOGA nanocomposite at equilibrium did not
reach 100 %, which can be attributed to the charac-
teristics of the ion-exchange reaction mechanism, i.e.,
the loaded anions cannot be exchanged completely at
equilibrium, but the organic species released was removed
continuously [52]. These results show that the GOGA
nanocomposite has a good potential to be used as a drug
delivery system with controlled sustained release property.
Release Kinetics of GA from GOGA Nanocomposite
The kinetic release of GA from the GOGA nanocompos-
ite was fitted using a number of different kinetic models,
such as pseudo-first order (Eq. 1), pseudo-second order
(Eq. 2), parabolic diffusion (Eq. 3), Higuchi Model (Eq. 4),
Fig. 4 HRTEM images of a GO nanocarrier with 200 nm bar, b GO nanocarrier with 50 nm bar, c GOGA nanocomposite with 100 nm bar, and d
GOGA nanocomposite with 50 nm bar
a b
Fig. 5 Release profiles for a physical mixture of GA and b GOGA nanocomposite in phosphate-buffered solution at pH 7.4
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and Korsmeyer-Peppas Model (Eq. 5) [53, 54]. The
equations are shown below
ln qe− qtð Þ ¼ ln qe− kt ð1Þ
t=qt ¼ 1=kqe2 þ t=qe ð2Þ
1 −Mt=M0ð Þ=t ¼ kt−0:5 þ b ð3Þ
qt ¼ K
ﬃﬃ
t
p ð4Þ
qt=q∞ ¼ Ktn ð5Þ
where k is the corresponding release amount constant,
qe and qt are the equilibrium release amount and the
release amount at time t, respectively, and M0 and Mt
represent the drug (GA) content remaining in the GO
nanocarrier at release times 0 and t, respectively.
The Higuchi equation plot (Fig. 6d) with correlation
coefficient (R2 = 0.9550) shows the release of the drug
from the GOGA matrix a square root of time and is
dependent on Fickian diffusion. The results (Fig. 6 and
Table 1) indicated that the release of the active drug,
GA, from the GOGA nanocomposite followed the
pseudo-second-order kinetic model, with a best fit
value for the correlation coefficient (R2 = 0.9989), as
shown in Fig. 6 and Table 1. In addition, the t1/2 time
release of GA into phosphate-buffered solution at pH
7.4 was 203 min using pseudo-second-order kinetic
model (Table 1).
a b
c
e
d
Fig. 6 Fitting the data of GA release from GOGA nanocomposite at pH 7.4 for kinetic models a pseudo-first order, b pseudo-second order, c
parabolic diffusion, d Higuchi model, and e korsmeyer-peppas model
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Inhibition of Cancer Cell Growth by the Nanocompound
The potential cytotoxicity of GO carrier, GA, and
GOGA nanocomposite on proliferation of normal fibro-
blast cells and cancer cells on preliminary screening
results is shown in Fig. 7. In the normal fibroblast cells
(Fig. 7a), we did not notice any cytotoxicity effect up to
the highest concentration of 50 μg/mL. Therefore, the
GOGA nanocomposite is safe to use for further experi-
ments. In the liver cancer cells (Fig. 7b), the percentages
of viable cells were decreased in a dose-dependent man-
ner. The results show that GO nanocarrier had a
negligible effect in liver cancer cells, with almost 100 %
of cells remaining viable at 50 μg/mL compared with
about 48 % of cells remaining viable for GOGA
nanocomposite. Thus, the cytotoxicity to the liver cells
is likely attributable to the release of GA from the GO
carrier rather than the effect of the carrier itself. This
result shows that the anticancer activity of our new
nanocomposite is very similar to that of pure GA and
suggests the possibility of a decreased dosing interval
due to the sustained-release ability of the nanocompos-
ite. With the sustained release and possible targeted
delivery potential of GOGA nanocomposite, the least
amount of active agent (GA) could suffice, hence redu-
cing the dosing interval and unnecessary exposure to
large quantities of this hazardous drug.
The results further suggest the possibility of increased
anticancer activity with increasing the loading percent-
age. The IC50 values are 429.5, 42.9, and 38.9 μg/mL for
GO nanocarrier, GOGA nanocomposite, and GA, re-
spectively. These results have suggested that GO-based
nanocarrier is one of the good candidates for drug deliv-
ery system against cancer cells, without showing notice-
able cytotoxicity in normal fibroblast cells.
Conclusions
In this study, we report the design and synthesis of
an anticancer nanodelivery systems based on a gra-
phene oxide-gallic acid nanocomposite. The empty
carrier GO and designed anticancer nanocomposite
(GOGA) was found to be highly biocompatible with
normal fibroblast cells. The designed GOGA nano-
composite showed good anticancer activity against
liver cancer (HepG2) cells. The results show that
cytotoxicity to the liver cells is likely attributable to
the release of GA from the carrier rather than the
effect of the carrier itself. And due to the similar an-
ticancer activity of our new nanocomposite to that of
pure GA, the possibility of a decreased dosing inter-
val due to the sustained-release ability of the nano-
composite can be suggested. Therefore, the least
amount of active drug (GA) could suffice, hence
reducing the dosing interval and unnecessary expos-
ure to large quantities of this drug. Sustained release
of active agent (GA) over longer period of time
(6800 min) will increase the viability of drug and
would ultimately result in better therapeutic efficacy
and decreasing in drug dosing frequency. These in
vitro studies have encouraged this research towards
the next level of in vivo studies.
Table 1 Correlation coefficients (R2), rate constant (k), and half-time (t1/2) obtained by fitting the GA release data from the GOGA
nanocomposite into phosphate-buffered solution at pH 7.4
Aqueous
solution
Saturated
release (%)
R2 Rate constant
(k)a (mg/min)
t1/2
a (min)
Pseudo-first order Pseudo-second order Parabolic diffusion Higuchi model Korsmeyer-peppas
model
pH 7.4 83.1 0.3294 0.9832 0.9550 0.9550 0.9785 2.42 × 10−4 203
aEstimated using pseudo-second-order kinetics
a
b
Fig. 7 Cytotoxic effects of GO, GOGA, and GA on the normal
fibroblast cells and HepG2 liver cancer cells. Normal fibroblast cells
3T3 (a) and HepG2 (b) cells were treated with different doses of
carrier, pure drug, and GOGA nanocomposite for 72 h and
cytotoxicity was measured using a CCK-8 assay kit and the results
were calculated according to the kit protocol and results are
expressed as mean ± SD
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